Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02705638 · ClinicalTrials.gov registry record · Phase 1
Treatment of IgG4-Related Disease With Revlimid and Rituximab
A Phase 1 study of IgG4 Related Disease and Autoimmune Pancreatitis, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT02705638: Completed Phase 1 study of IgG4 Related Disease and Autoimmune Pancreatitis, sponsored by Mayo Clinic.
NCT02705638 is a Phase 1 study of IgG4 Related Disease and Autoimmune Pancreatitis that has completed, run by Mayo Clinic. The registered enrollment target is 6 participants, below the 91-participant average among 4 other IgG4 Related Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02705638, a Phase 1 study of IgG4 Related Disease and Autoimmune Pancreatitis, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
Among persons with Immunoglobulin G subclass 4 Related Disease (IgG4)-related disease who have persistent or recurrent disease despite standard therapies, does combination therapy with rituximab and revlimid cause a sustained disease remission?
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG Lenalidomide
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-04 |
| Est. Completion | 2019-04 |
| Phase | Phase 1 |
What the finished NCT02705638 record still lists
NCT02705638 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 91-participant average among 4 other IgG4 Related Disease trials with a reported enrollment target (93% lower).
The record links to 5 conditions, with IgG4 Related Disease appearing as the primary indexed condition, and to 2 interventions - of which Rituximab is the first listed.
NCT02705638 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02705638 about?
NCT02705638 is a clinical study titled "Treatment of IgG4-Related Disease With Revlimid and Rituximab". Among persons with Immunoglobulin G subclass 4 Related Disease (IgG4)-related disease who have persistent or recurrent disease despite standard therapies, does combination therapy with rituximab and revlimid cause a sustained disease remission?
What is the current status of trial NCT02705638?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2016-04. Estimated completion is 2019-04.
What conditions does trial NCT02705638 study?
This clinical trial studies the following conditions: IgG4 Related Disease, Autoimmune Pancreatitis, Immunoglobulin G Subclass 4 Related Disease, IgG4-related Sclerosing Cholangitis, Retroperitoneal Fibrosis.
What interventions are being tested in trial NCT02705638?
The interventions under investigation include: Rituximab (DRUG), Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT02705638?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02705638 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IgG4 Related Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
RECRUITING · Phase 1
-
A Study of Efgartigimod in Patients With IgG4-Related Disease
RECRUITING · Phase 2
-
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia